scholarly journals Basal forebrain volume reliably predicts the cortical spread of Alzheimer’s degeneration

2019 ◽  
Author(s):  
Sara Fernández-Cabello ◽  
Martin Kronbichler ◽  
Koene R. A. Van Dijk ◽  
James A. Goodman ◽  
R. Nathan Spreng ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Gray Matter ◽  
Basal Forebrain ◽  
Temporal Cortex ◽  
Predictive Modelling ◽  
Nucleus Basalis ◽  
Longitudinal Change ◽  
Seed Region ◽  
Projection System

AbstractAlzheimer’s disease neuropathology is thought to spread across anatomically and functionally connected brain regions. However, the precise sequence of spread remains ambiguous. The prevailing model posits that Alzheimer’s neurodegeneration starts in the entorhinal cortices, before spreading to temporoparietal cortex. Challenging this model, we previously provided evidence that degeneration within the nucleus basalis of Meynert (NbM), a subregion of the basal forebrain heavily populated by cortically projecting cholinergic neurons, precedes and predicts entorhinal degeneration (Schmitz and Spreng, 2016). There have been few systematic attempts at directly comparing staging models using in vivo longitudinal biomarker data, and determining if these comparisons generalize across independent samples. Here we addressed the sequence of pathological staging in Alzheimer’s disease using two independent samples of the Alzheimer’s Disease Neuroimaging Initiative (N1 = 284; N2 = 553) with harmonized CSF assays of amyloid (Aβ) and hyperphosphorylated tau (pTau), and longitudinal structural MRI data over two years. We derived measures of gray matter degeneration in a priori NbM and the entorhinal regions of interest. To examine the spreading of degeneration, we used a predictive modelling strategy which tests whether baseline gray matter volume in a seed region accounts for longitudinal change in a target region. We demonstrated that predictive pathological spread favored the NbM→entorhinal over the entorhinal→NbM model. This evidence generalized across the independent samples (N1: r=0.20, p=0.03; N2: r=0.37, p<0.001). We also showed that CSF concentrations of pTau/Aβ moderated the observed predictive relationship, consistent with evidence in rodent models of an underlying trans-synaptic mechanism of pathophysiological spread (t826=2.55, p=0.01). The moderating effect of CSF was robust to additional factors, including clinical diagnosis (t826=1.65, p=0.49). We then applied our predictive modelling strategy to an exploratory whole-brain voxel-wise analysis to examine the spatial specificity of the NbM→entorhinal model. We found that smaller baseline NbM volumes predicted greater degeneration in localized regions of the entorhinal and perirhinal cortices. By contrast, smaller baseline entorhinal volumes predicted degeneration in the medial temporal cortex, recapitulating the prevailing staging model. Our findings suggest that degeneration of the basal forebrain cholinergic projection system is a robust and reliable upstream event of entorhinal and neocortical degeneration, calling into question the prevailing view of Alzheimer’s disease pathogenesis.

scholarly journals Basal forebrain volume reliably predicts the cortical spread of Alzheimer’s degeneration

Brain ◽  
2020 ◽  
Vol 143 (3) ◽  
pp. 993-1009 ◽  
Author(s):  
Sara Fernández-Cabello ◽  
Martin Kronbichler ◽  
Koene R A Van Dijk ◽  
James A Goodman ◽  
R Nathan Spreng ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Basal Forebrain ◽  
Grey Matter ◽  
Amyloid Β ◽  
Predictive Modelling ◽  
Nucleus Basalis ◽  
Seed Region ◽  
Projection System

Abstract Alzheimer’s disease neurodegeneration is thought to spread across anatomically and functionally connected brain regions. However, the precise sequence of spread remains ambiguous. The prevailing model used to guide in vivo human neuroimaging and non-human animal research assumes that Alzheimer’s degeneration starts in the entorhinal cortices, before spreading to the temporoparietal cortex. Challenging this model, we previously provided evidence that in vivo markers of neurodegeneration within the nucleus basalis of Meynert (NbM), a subregion of the basal forebrain heavily populated by cortically projecting cholinergic neurons, precedes and predicts entorhinal degeneration. There have been few systematic attempts at directly comparing staging models using in vivo longitudinal biomarker data, and none to our knowledge testing if comparative evidence generalizes across independent samples. Here we addressed the sequence of pathological staging in Alzheimer’s disease using two independent samples of the Alzheimer’s Disease Neuroimaging Initiative (n1 = 284; n2 = 553) with harmonized CSF assays of amyloid-β and hyperphosphorylated tau (pTau), and longitudinal structural MRI data over 2 years. We derived measures of grey matter degeneration in a priori NbM and the entorhinal cortical regions of interest. To examine the spreading of degeneration, we used a predictive modelling strategy that tests whether baseline grey matter volume in a seed region accounts for longitudinal change in a target region. We demonstrated that predictive spread favoured the NbM→entorhinal over the entorhinal→NbM model. This evidence generalized across the independent samples. We also showed that CSF concentrations of pTau/amyloid-β moderated the observed predictive relationship, consistent with evidence in rodent models of an underlying trans-synaptic mechanism of pathophysiological spread. The moderating effect of CSF was robust to additional factors, including clinical diagnosis. We then applied our predictive modelling strategy to an exploratory whole-brain voxel-wise analysis to examine the spatial specificity of the NbM→entorhinal model. We found that smaller baseline NbM volumes predicted greater degeneration in localized regions of the entorhinal and perirhinal cortices. By contrast, smaller baseline entorhinal volumes predicted degeneration in the medial temporal cortex, recapitulating a prior influential staging model. Our findings suggest that degeneration of the basal forebrain cholinergic projection system is a robust and reliable upstream event of entorhinal and neocortical degeneration, calling into question a prevailing view of Alzheimer’s disease pathogenesis.

scholarly journals Atrophy of Basal Forebrain Initiates with Tau Pathology in Individuals at Risk for Alzheimer’s Disease

2019 ◽  
Vol 30 (4) ◽  
pp. 2083-2098
Author(s):  
Jose L Cantero ◽  
Mercedes Atienza ◽  
Carmen Lage ◽  
Laszlo Zaborszky ◽  
Eduard Vilaplana ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
At Risk ◽  
Basal Forebrain ◽  
Cholinergic Neurons ◽  
Nucleus Basalis ◽  
Tau Pathology ◽  
Projection System ◽  
Prodromal Ad

Abstract Evidence suggests that the basal forebrain (BF) cholinergic system degenerates early in the course of Alzheimer’s disease (AD), likely due to the vulnerability of BF cholinergic neurons to tau pathology. However, it remains unclear whether the presence of tauopathy is the only requirement for initiating the BF degeneration in asymptomatic subjects at risk for AD (AR-AD), and how BF structural deficits evolve from normal aging to preclinical and prodromal AD. Here, we provide human in vivo magnetic resonance imaging evidence supporting that abnormal cerebrospinal fluid levels of phosphorylated tau (T+) are selectively associated with bilateral volume loss of the nucleus basalis of Meynert (nbM, Ch4) in AR-AD individuals. Spreading of atrophy to medial septum and vertical limb of diagonal band Broca (Ch1–Ch2) occurred in both preclinical and prodromal AD. With the exception of A+, all groups revealed significant correlations between volume reduction of BF cholinergic compartments and atrophy of their innervated regions. Overall, these results support the central role played by tauopathy in instigating the nbM degeneration in AR-AD individuals and the necessary coexistence of both AD proteinopathies for spreading damage to larger BF territories, thus affecting the core of the BF cholinergic projection system.

Nucleus basalis neuronal loss and neuritic plaques in advanced Alzheimer's disease

1986 ◽  
Vol 64 (3) ◽  
pp. 318-324 ◽  
Author(s):  
Pierre Etienne ◽  
Yves Robitaille ◽  
Serge Gauthier ◽  
N. P. V. Nair
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Basal Forebrain ◽  
Neuronal Loss ◽  
Cell Loss ◽  
Nucleus Basalis ◽  
Nucleus Basalis Of Meynert ◽  
Neuritic Plaques ◽  
Cholinergic Cell

All our advanced severe cases of Alzheimer's disease had dramatic cholinergic cell loss in the basal forebrain, even after correction for cell or nucleolus shrinkage. We examined the relation between cell loss in the various subdivisions of the nucleus basalis of Meynert and plaque counts in corresponding and noncorresponding projection areas. This relation was not interpretable because of the ambiguity in the data.

Basal forebrain atrophy along the Alzheimer’s disease spectrum and its relevance for subjective cognitive decline

2020 ◽  
Author(s):  
Shumei Li ◽  
Michel J. Grothe ◽  
Marcel Daamen ◽  
Steffen Wolfsgruber ◽  
Frederic Brosseron ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Cognitive Decline ◽  
Basal Forebrain ◽  
Nucleus Basalis ◽  
Nucleus Basalis Of Meynert ◽  
Subjective Cognitive Decline ◽  
Healthy Controls ◽  
Cholinergic Basal Forebrain

Abstract Background There is growing evidence in the literature that the cholinergic basal forebrain might be one of the earliest affected structures in Alzheimer’s disease (AD). Recent data suggest that individuals with preclinical Alzheimer’s pathology already show atrophy of the posterior nucleus basalis of Meynert and that this even precedes the atrophy of the entorhinal cortex. Here we investigated whether basal forebrain volume reductions might not only be detectable in the mild cognitive impairment (MCI) and dementia stage of AD, but also in subjective cognitive decline (SCD) individuals who represent an at-risk population for preclinical AD, and examine the relationship with cognitive performance and amyloid-beta pathology. Methods Basal forebrain volumes of 341 participants from the multi-center German Center for Neurodegenerative Diseases Longitudinal Cognitive Impairment and Dementia Study, including 135 healthy controls, 110 SCD, 60 MCI, and 36 AD, were analyzed using high-resolution T1-weighted images. Healthy controls and SCD participants were further grouped into amyloid-positive and amyloid-negative cases according to their cerebrospinal fluid Aβ42/40 ratio. Associations between basal forebrain volume, neuropsychological performance, and amyloid load were evaluated. Results Apart from confirming progressive basal forebrain atrophy from MCI to AD, atrophy of the posterior of nucleus basalis of Meynert was also observed in subjective cognitive decline with confirmed evidence for preclinical Alzheimer’s pathology, based on the Aβ42/40 ratio. This atrophy was neither evident in subjects with SCD without amyloid pathology nor in healthy controls with amyloid pathology. Additionally, the volume of the posterior of nucleus basalis of Meynert was significantly correlated with amyloid Aβ42/40 ratio in SCD but not in healthy controls. Conclusion Our results confirm that basal forebrain atrophy occurs early along the Alzheimer’s disease trajectory. The observed volume reduction of the cholinergic basal forebrain in Aβ-positive participants with subjective cognitive complains and the absence of any volume reductions in the Aβ-positive healthy controls suggests that these ‘subjective cognitive decline’ symptoms reflect progression from stage 1 (asymptomatic) to stage 2 (transitional cognitive impairment) of the Alzheimer’s continuum (according to the recent National Institute on Aging-Alzheimer’s Association Research Framework), revealing the beginning neurodegeneration on a macroscopic level.

scholarly journals Structural (dys)connectivity associates with cholinergic cell density of the nucleus basalis of Meynert in Alzheimer's disease

2021 ◽  
Author(s):  
Chen-Pei Lin ◽  
Irene Frigerio ◽  
Baayla DC Boon ◽  
Zihan Zhou ◽  
Annemieke JM Rozemuller ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cell Density ◽  
Temporal Lobe ◽  
Basal Forebrain ◽  
Amyloid Β ◽  
Nucleus Basalis ◽  
Nucleus Basalis Of Meynert ◽  
Phosphorylated Tau ◽  
Cholinergic Cell

Cognitive deficits in Alzheimer's disease, specifically amnestic (memory dominant) deficits, are associated with cholinergic degeneration in the basal forebrain. The cholinergic nucleus within the basal forebrain, the nucleus basalis of Meynert, exhibits local atrophy and reduced cortical tract integrity on MRI, and reveals amyloid-β and phosphorylated-tau pathology at autopsy. To better understand the pathophysiology of nucleus basalis of Meynert atrophy and its neocortical projections in Alzheimer's disease, we utilized a combined post-mortem in-situ MRI and histopathology approach. A total of 19 Alzheimer's disease (10 amnestic and 9 non-amnestic) and 9 non-neurological control donors underwent 3T T1-weighted MRI for anatomical delineation and volume assessment of the nucleus basalis of Meynert, and diffusion-weighted imaging for microstructural assessment of the nucleus and its projections. At subsequent brain autopsy, tissue dissection and immunohistochemistry were performed for amyloid-β, phosphorylated-tau and choline acetyltransferase. Compared to controls, we observed an MRI-derived volume reduction and altered microstructural integrity of the nucleus basalis of Meynert in Alzheimer's disease donors. Furthermore, decreased cholinergic cell density was associated with reduced integrity of the nucleus and its tracts to the temporal lobe, specifically to the temporal pole of the superior temporal gyrus, and the parahippocampal gyrus. The association between cholinergic cell density and alteration to cortical tracts was specific for amnestic, compared to non-amnestic Alzheimer's disease donors. Our study illustrates that the nucleus basalis of Meynert is severely affected in amnestic Alzheimer's disease, both in terms of pathology within the nucleus, but also in terms of damage to its cortical projections, specifically to the temporal lobe, which may contribute to the observed cognitive deterioration.

scholarly journals Topographic patterns of white matter hyperintensities are associated with multimodal neuroimaging biomarkers of Alzheimer’s disease

2021 ◽  
Vol 13 (1) ◽  
Author(s):  
Malo Gaubert ◽  
Catharina Lange ◽  
Antoine Garnier-Crussard ◽  
Theresa Köbe ◽  
Salma Bougacha ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
White Matter ◽  
Glucose Metabolism ◽  
Corpus Callosum ◽  
Gray Matter ◽  
Fdg Pet ◽  
White Matter Hyperintensities ◽  
Gray Matter Volume ◽  
Matter Volume

Abstract Background White matter hyperintensities (WMH) are frequently found in Alzheimer’s disease (AD). Commonly considered as a marker of cerebrovascular disease, regional WMH may be related to pathological hallmarks of AD, including beta-amyloid (Aβ) plaques and neurodegeneration. The aim of this study was to examine the regional distribution of WMH associated with Aβ burden, glucose hypometabolism, and gray matter volume reduction. Methods In a total of 155 participants (IMAP+ cohort) across the cognitive continuum from normal cognition to AD dementia, FLAIR MRI, AV45-PET, FDG-PET, and T1 MRI were acquired. WMH were automatically segmented from FLAIR images. Mean levels of neocortical Aβ deposition (AV45-PET), temporo-parietal glucose metabolism (FDG-PET), and medial-temporal gray matter volume (GMV) were extracted from processed images using established AD meta-signature templates. Associations between AD brain biomarkers and WMH, as assessed in region-of-interest and voxel-wise, were examined, adjusting for age, sex, education, and systolic blood pressure. Results There were no significant associations between global Aβ burden and region-specific WMH. Voxel-wise WMH in the splenium of the corpus callosum correlated with greater Aβ deposition at a more liberal threshold. Region- and voxel-based WMH in the posterior corpus callosum, along with parietal, occipital, and frontal areas, were associated with lower temporo-parietal glucose metabolism. Similarly, lower medial-temporal GMV correlated with WMH in the posterior corpus callosum in addition to parietal, occipital, and fontal areas. Conclusions This study demonstrates that local white matter damage is correlated with multimodal brain biomarkers of AD. Our results highlight modality-specific topographic patterns of WMH, which converged in the posterior white matter. Overall, these cross-sectional findings corroborate associations of regional WMH with AD-typical Aß deposition and neurodegeneration.

Reproducibility of Brain Volume Changes in Longitudinal Voxel-Based Morphometry Between Non-Accelerated and Accelerated Magnetic Resonance Imaging

2021 ◽  
pp. 1-10
Author(s):  
Hidemasa Takao ◽  
Shiori Amemiya ◽  
Osamu Abe ◽  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Magnetic Resonance ◽  
Gray Matter ◽  
Gray Matter Volume ◽  
Elderly Subjects ◽  
Voxel Based Morphometry ◽  
Volume Changes ◽  
Matter Volume ◽  
Healthy Elderly

Background: Scan acceleration techniques, such as parallel imaging, can reduce scan times, but reliability is essential to implement these techniques in neuroimaging. Objective: To evaluate the reproducibility of the longitudinal changes in brain morphology determined by longitudinal voxel-based morphometry (VBM) between non-accelerated and accelerated magnetic resonance images (MRI) in normal aging, mild cognitive impairment (MCI), and Alzheimer’s disease (AD). Methods: Using data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) 2 database, comprising subjects who underwent non-accelerated and accelerated structural T1-weighted MRI at screening and at a 2-year follow-up on 3.0 T Philips scanners, we examined the reproducibility of longitudinal gray matter volume changes determined by longitudinal VBM processing between non-accelerated and accelerated imaging in 50 healthy elderly subjects, 54 MCI patients, and eight AD patients. Results: The intraclass correlation coefficient (ICC) maps differed among the three groups. The mean ICC was 0.72 overall (healthy elderly, 0.63; MCI, 0.75; AD, 0.63), and the ICC was good to excellent (0.6–1.0) for 81.4%of voxels (healthy elderly, 64.8%; MCI, 85.0%; AD, 65.0%). The differences in image quality (head motion) were not significant (Kruskal–Wallis test, p = 0.18) and the within-subject standard deviations of longitudinal gray matter volume changes were similar among the groups. Conclusion: The results indicate that the reproducibility of longitudinal gray matter volume changes determined by VBM between non-accelerated and accelerated MRI is good to excellent for many regions but may vary between diseases and regions.

Sign in / Sign up

Export Citation Format

Share Document